PDF(Pubmed)
Abstract：
BACKGROUND: Extensive evidence has suggested the cardio-protective properties of the polyphenol curcumin. The aim of this study was to investigate the effects of a highly bioavailable curcumin supplement on cardiometabolic risk factors, health-related quality of life, and depression in patients with coronary slow flow phenomenon (CSFP).
METHODS: This randomized double-blind placebo-controlled clinical trial was conducted in 42 patients with CSFP (age 35-70 years, 25 ≤ body mass index < 40 kg/m2). Patients received either 80 mg/day nano-curcumin or placebo for 12 weeks. Serum levels of visfatin, high-sensitivity C-reactive protein (hs-CRP), and glycemic indices were measured before and after the intervention. The short form 36-item quality of life (SF-36) and Beck\'s Depression Inventory-II (BDI-II) questionnaires were assessed, as well.
RESULTS: No significant improvements were observed in circulating hs-CRP and visfatin following the intervention. A significant increase was observed in pre- to post-fasting blood glucose (- 0.9 ± 12.2 vs. 7.7 ± 12.4 mg/dl, p = 0.02) and hemoglobin A1C (- 0.1 ± 0.8 vs. 0.5 ± 0.8%, p = 0.04) levels, in the placebo compared with the intervention group. Physical (8.2 ± 8.1 vs. - 1.2 ± 6.5, p < 0.001) and mental (6.8 ± 11.8 vs. - 1.1 ± 10.4, p = 0.02) component summary scores were significantly improved in the nano-curcumin than the placebo group. Additionally, the number of patients with lower degrees of depression was significantly better in the intervention than the placebo group following the supplementation (p = 0.046).
CONCLUSIONS: Curcumin supplementation prevented deterioration of glycemic control and improved physical and psychological quality of life and depression in patients with CSFP.
BACKGROUND: Iranian Registry of Clinical Trials (IRCT20131125015536N8), June 19, 2019.
METHODS: This randomized double-blind placebo-controlled clinical trial was conducted in 42 patients with CSFP (age 35-70 years, 25 ≤ body mass index < 40 kg/m2). Patients received either 80 mg/day nano-curcumin or placebo for 12 weeks. Serum levels of visfatin, high-sensitivity C-reactive protein (hs-CRP), and glycemic indices were measured before and after the intervention. The short form 36-item quality of life (SF-36) and Beck\'s Depression Inventory-II (BDI-II) questionnaires were assessed, as well.
RESULTS: No significant improvements were observed in circulating hs-CRP and visfatin following the intervention. A significant increase was observed in pre- to post-fasting blood glucose (- 0.9 ± 12.2 vs. 7.7 ± 12.4 mg/dl, p = 0.02) and hemoglobin A1C (- 0.1 ± 0.8 vs. 0.5 ± 0.8%, p = 0.04) levels, in the placebo compared with the intervention group. Physical (8.2 ± 8.1 vs. - 1.2 ± 6.5, p < 0.001) and mental (6.8 ± 11.8 vs. - 1.1 ± 10.4, p = 0.02) component summary scores were significantly improved in the nano-curcumin than the placebo group. Additionally, the number of patients with lower degrees of depression was significantly better in the intervention than the placebo group following the supplementation (p = 0.046).
CONCLUSIONS: Curcumin supplementation prevented deterioration of glycemic control and improved physical and psychological quality of life and depression in patients with CSFP.
BACKGROUND: Iranian Registry of Clinical Trials (IRCT20131125015536N8), June 19, 2019.
摘要：
背景：大量证据表明多酚姜黄素具有心脏保护特性。这项研究的目的是研究高生物利用度姜黄素补充剂对心脏代谢危险因素的影响。与健康相关的生活质量，和抑郁患者的冠状动脉慢血流现象(CSFP)。
方法：这项随机双盲安慰剂对照临床试验在42名CSFP患者中进行（年龄35-70岁，25≤体重指数<40kg/m2)。患者接受80毫克/天的纳米姜黄素或安慰剂治疗12周。血清内脂素水平，高敏C反应蛋白(hs-CRP),在干预前后测量血糖指数。简表36项生活质量（SF-36）和贝克抑郁量表-II（BDI-II）问卷进行评估，也是。
结果：干预后，循环hs-CRP和内脂素没有显著改善。空腹前后血糖显着增加（-0.9±12.2vs.7.7±12.4mg/dl，p=0.02）和血红蛋白A1C（-0.1±0.8vs.0.5±0.8%,p=0.04)水平，与干预组相比，安慰剂组。物理（8.2±8.1vs.-1.2±6.5，p<0.001）和精神（6.8±11.8vs.-1.1±10.4，p=0.02）纳米姜黄素组的成分汇总得分比安慰剂组显着提高。此外,在补充药物后,干预组抑郁程度较低的患者数量明显优于安慰剂组(p=0.046).
结论：补充姜黄素可以防止CSFP患者血糖控制恶化，并改善其生理和心理生活质量和抑郁。
背景：伊朗临床试验注册（IRCT20131125015536N8），2019年6月19日。
方法：这项随机双盲安慰剂对照临床试验在42名CSFP患者中进行（年龄35-70岁，25≤体重指数<40kg/m2)。患者接受80毫克/天的纳米姜黄素或安慰剂治疗12周。血清内脂素水平，高敏C反应蛋白(hs-CRP),在干预前后测量血糖指数。简表36项生活质量（SF-36）和贝克抑郁量表-II（BDI-II）问卷进行评估，也是。
结果：干预后，循环hs-CRP和内脂素没有显著改善。空腹前后血糖显着增加（-0.9±12.2vs.7.7±12.4mg/dl，p=0.02）和血红蛋白A1C（-0.1±0.8vs.0.5±0.8%,p=0.04)水平，与干预组相比，安慰剂组。物理（8.2±8.1vs.-1.2±6.5，p<0.001）和精神（6.8±11.8vs.-1.1±10.4，p=0.02）纳米姜黄素组的成分汇总得分比安慰剂组显着提高。此外,在补充药物后,干预组抑郁程度较低的患者数量明显优于安慰剂组(p=0.046).
结论：补充姜黄素可以防止CSFP患者血糖控制恶化，并改善其生理和心理生活质量和抑郁。
背景：伊朗临床试验注册（IRCT20131125015536N8），2019年6月19日。
